2936622-49-8
Chemical Structure
Trihydroxycholestanoic acid-d5
Synonym(s): Coprocholic acid-d5
- CAS No.: 2936622-49-8
- Formula:C27H41D5O5
- Molecular Weight:455.68
InChIKey: CNWPIIOQKZNXBB-OZOMSTKCSA-N
SMILES: O[C@H]1[C@@]2([H])[C@@]3([H])[C@@]([C@@](CC3)([H])[C@H](C)CCC([2H])([2H])C(C([2H])([2H])[2H])C(O)=O)([C@H](C[C@]2([H])[C@@]4([C@](C[C@@H](CC4)O)([H])C1)C)O)C
Biological Activity: Trihydroxycholestanoic acid-d5 (Coprocholic acid-d5) is deuterium labeled Trihydroxycholestanoic acid. Trihydroxycholestanoic acid is an endogenous metabolite present in Blood that can be used for the research of Zellweger Syndrome, Refsum Disease, D Bifunctional Protein Deficiency and Infantile Refsum Disease[1][2][3][4][1][2][3][4][5].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Trihydroxycholestanoic acid-d5 | Trihydroxycholestanoic acid-d5 (Coprocholic acid-d5) is deuterium labeled Trihydroxycholestanoic acid. Trihydroxycholestanoic acid is an endogenous metabolite present in Blood that can be used for the research of Zellweger Syndrome, Refsum Disease, D Bifunctional Protein Deficiency and Infantile Refsum Disease. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Trihydroxycholestanoic acid-d3 | Trihydroxycholestanoic acid-d3 is the deuterium labeled Trihydroxycholestanoic acid. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Trihydroxycholestanoic acid | 99.48% | Trihydroxycholestanoic acid is an endogenous metabolite present in Blood that can be used for the research of Zellweger Syndrome, Refsum Disease, D Bifunctional Protein Deficiency and Infantile Refsum Disease. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
- [1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019 Feb;53(2):211-216. [Content Brief]
- [2]. Lee N, et al. Endogenous toxic metabolites and implications in cancer therapy. Oncogene. 2020 Aug;39(35):5709-5720. [Content Brief]
- [3]. Baumgartner MR, et al. Clinical approach to inherited peroxisomal disorders: a series of 27 patients. Ann Neurol. 1998 Nov;44(5):720-30. [Content Brief]
- [4]. Poll-The BT, et al. Infantile Refsum's disease: biochemical findings suggesting multiple peroxisomal dysfunction. J Inherit Metab Dis. 1986;9(2):169-74. [Content Brief]
- [5]. Rizzo C, et al. Characteristic acylcarnitine profiles in inherited defects of peroxisome biogenesis: a novel tool for screening diagnosis using tandem mass spectrometry. Pediatr Res. 2003 Jun;53(6):1013-8. [Content Brief]
